Table 1.

Baseline characteristics of Medicaid-Medicare Dual Eligibles and Medicaid-only participants, Women’s Interagency HIV Study (2005)

	Unmatched sample (n=801)			Propensity score-matched sample (n=236)

	Dual Eligibles (n=125)	Medicaid-only (n=676)	p-value^a	Dual Eligibles (n=118)	Medicaid-only (n=118)	p-value^a

Age in years, median (IQR)	47 (41, 52)	43 (38, 49)	0.005	46 (41, 52)	46 (41, 52)	0.603
African American, %	56.5	67.9	0.014	59.0	64.4	0.394
Hispanic ethnicity, %	24.2	26.6	0.575	23.9	23.7	0.971
WIHS site, %
Bronx	15.2	28.7	0.002	16.1	23.7	0.144
Brooklyn	20.0	23.5	0.391	20.3	16.9	0.506
Washington, DC	08.0	08.6	0.831	08.5	11.9	0.391
Los Angeles	20.0	11.0	0.005	19.5	15.3	0.393
San Francisco	24.0	15.1	0.014	22.0	17.8	0.417
Chicago	12.8	13.2	0.912	13.6	14.4	0.852
ADAP	10.4	05.1	0.019	07.7	07.6	0.985
Any out-of-pocket prescription spending, %	22.8	12.9	0.004	21.6	14.5	0.165
100% ART adherent^b	51.2	43.2	0.127	51.2	48.4	0.719
CES-D, median (IQR)	14 (3.5, 28.5)	15 (6, 25)	0.844	14 (3, 27)	15 (4, 27)	0.698
Household income <$12,000/year, %	62.1	67.1	0.278	62.2	60.9	0.849
Graduated high school, %	76.4	48.1	<0.0001	25.5	27.0	0.792
Employed, %	12.9	18.6	0.129	12.1	10.0	0.558
CD4 cell count, median (IQR)	466 (312, 643)	416 (249, 622)	0.265	484 (324, 658)	476 (316, 728)	0.396
Virally suppressed^c, %	59.3	48.0	0.021	59.6	64.7	0.447

Abbreviations: ADAP, AIDS Drug Assistance Programs; ART, antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale; IQR, interquartile range; HIV, Human Immunodeficiency Virus; WIHS, Women’s Interagency HIV Study

Statistical significance tested using t tests

Proportions calculated within subset of dual eligibles (n=103) and Medicaid-only participants (n=461) on ART

Viral suppression corresponds to a VL measurement of <200 copies/mL